Cargando…

Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level

Introduction: Cierny–Mader osteomyelitis classification is used to label A, B, or C hosts based on comorbidities. This study's purpose was to define the “true” host status of patients with orthopedic infection using serologic markers to quantify the competence of their immune system while activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Conway, Janet D., Hambardzumyan, Vache, Patel, Nirav G., Giacobbe, Shawn D., Gesheff, Martin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Copernicus GmbH 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663624/
https://www.ncbi.nlm.nih.gov/pubmed/34909368
http://dx.doi.org/10.5194/jbji-6-433-2021
_version_ 1784613681102848000
author Conway, Janet D.
Hambardzumyan, Vache
Patel, Nirav G.
Giacobbe, Shawn D.
Gesheff, Martin G.
author_facet Conway, Janet D.
Hambardzumyan, Vache
Patel, Nirav G.
Giacobbe, Shawn D.
Gesheff, Martin G.
author_sort Conway, Janet D.
collection PubMed
description Introduction: Cierny–Mader osteomyelitis classification is used to label A, B, or C hosts based on comorbidities. This study's purpose was to define the “true” host status of patients with orthopedic infection using serologic markers to quantify the competence of their immune system while actively infected. Methods: Retrospective chart review identified patients at a single-surgeon practice who were diagnosed with orthopedic infection between September 2013 and March 2020 and had immunological laboratory results. All patients were A or B hosts who underwent surgery to eradicate infection. Medical history, physical examination, and Cierny–Mader classification were recorded. Laboratory results included complement total, C3, C4, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin E (IgE), rheumatoid factor, and antineutrophil cytoplasmic antibodies (ANCA) panel. Clinically significant results were defined as flagged abnormal. Normal complement levels and normal IgG levels were considered abnormal when infection was present. Results: Of 105 patients, 99 (94 %) had documented lab abnormalities. Clinically significant abnormalities were found in 33 of 34 (97 %) type-A hosts and 66 of 71 (93 %) type-B hosts. Eleven of 105 (10.5 %) patients were formally diagnosed with primary immunodeficiency by a hematologist. IgG deficiency, of either low or normal value, in the face of infection comprised 91 % (30 of 34) type-A hosts and 86 % (56 of 71) type-B hosts. Six (5.7 %) patients received IgG replacement therapy. Twenty-eight patients had abnormal total complement levels (low or normal): 7.4 % (2 of 34) A hosts and 40 % (26 of 71) B hosts ( [Formula: see text] ). B hosts had statistically significantly lower complement levels and significantly more no-growth cultures ( [Formula: see text] ). Thirteen of 14 patients with recurrent infections had low or normal IgG levels. IgM was significantly lower between reinfected patients and those without reinfection ( [Formula: see text] ). Conclusions: Adding immunologic evaluation to the Cierny–Mader classification more accurately determines patients' true host status and better quantifies risk and outcome with respect to orthopedic infection. Immunologically deficient A hosts should be quantified as B hosts. IgG deficiencies may be addressed when deemed appropriate by the consulting hematologist/immunologist. Patients with recurrent infections had significantly lower IgM levels than their nonrecurrent infection counterparts.
format Online
Article
Text
id pubmed-8663624
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Copernicus GmbH
record_format MEDLINE/PubMed
spelling pubmed-86636242021-12-13 Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level Conway, Janet D. Hambardzumyan, Vache Patel, Nirav G. Giacobbe, Shawn D. Gesheff, Martin G. J Bone Jt Infect Original Full-Length Article Introduction: Cierny–Mader osteomyelitis classification is used to label A, B, or C hosts based on comorbidities. This study's purpose was to define the “true” host status of patients with orthopedic infection using serologic markers to quantify the competence of their immune system while actively infected. Methods: Retrospective chart review identified patients at a single-surgeon practice who were diagnosed with orthopedic infection between September 2013 and March 2020 and had immunological laboratory results. All patients were A or B hosts who underwent surgery to eradicate infection. Medical history, physical examination, and Cierny–Mader classification were recorded. Laboratory results included complement total, C3, C4, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin E (IgE), rheumatoid factor, and antineutrophil cytoplasmic antibodies (ANCA) panel. Clinically significant results were defined as flagged abnormal. Normal complement levels and normal IgG levels were considered abnormal when infection was present. Results: Of 105 patients, 99 (94 %) had documented lab abnormalities. Clinically significant abnormalities were found in 33 of 34 (97 %) type-A hosts and 66 of 71 (93 %) type-B hosts. Eleven of 105 (10.5 %) patients were formally diagnosed with primary immunodeficiency by a hematologist. IgG deficiency, of either low or normal value, in the face of infection comprised 91 % (30 of 34) type-A hosts and 86 % (56 of 71) type-B hosts. Six (5.7 %) patients received IgG replacement therapy. Twenty-eight patients had abnormal total complement levels (low or normal): 7.4 % (2 of 34) A hosts and 40 % (26 of 71) B hosts ( [Formula: see text] ). B hosts had statistically significantly lower complement levels and significantly more no-growth cultures ( [Formula: see text] ). Thirteen of 14 patients with recurrent infections had low or normal IgG levels. IgM was significantly lower between reinfected patients and those without reinfection ( [Formula: see text] ). Conclusions: Adding immunologic evaluation to the Cierny–Mader classification more accurately determines patients' true host status and better quantifies risk and outcome with respect to orthopedic infection. Immunologically deficient A hosts should be quantified as B hosts. IgG deficiencies may be addressed when deemed appropriate by the consulting hematologist/immunologist. Patients with recurrent infections had significantly lower IgM levels than their nonrecurrent infection counterparts. Copernicus GmbH 2021-12-01 /pmc/articles/PMC8663624/ /pubmed/34909368 http://dx.doi.org/10.5194/jbji-6-433-2021 Text en Copyright: © 2021 Janet D. Conway et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Full-Length Article
Conway, Janet D.
Hambardzumyan, Vache
Patel, Nirav G.
Giacobbe, Shawn D.
Gesheff, Martin G.
Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level
title Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level
title_full Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level
title_fullStr Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level
title_full_unstemmed Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level
title_short Immunological evaluation of patients with orthopedic infections: taking the Cierny–Mader classification to the next level
title_sort immunological evaluation of patients with orthopedic infections: taking the cierny–mader classification to the next level
topic Original Full-Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663624/
https://www.ncbi.nlm.nih.gov/pubmed/34909368
http://dx.doi.org/10.5194/jbji-6-433-2021
work_keys_str_mv AT conwayjanetd immunologicalevaluationofpatientswithorthopedicinfectionstakingtheciernymaderclassificationtothenextlevel
AT hambardzumyanvache immunologicalevaluationofpatientswithorthopedicinfectionstakingtheciernymaderclassificationtothenextlevel
AT patelniravg immunologicalevaluationofpatientswithorthopedicinfectionstakingtheciernymaderclassificationtothenextlevel
AT giacobbeshawnd immunologicalevaluationofpatientswithorthopedicinfectionstakingtheciernymaderclassificationtothenextlevel
AT gesheffmarting immunologicalevaluationofpatientswithorthopedicinfectionstakingtheciernymaderclassificationtothenextlevel